(22%) (15%) (10%) (9%) (40%) (< 10% )

Slides:

Advertisements

Similar presentations

Antimicrobial Prescribing in the Management of COPD

Advertisements

Infection in COPD Pulmonology Subspeciality Rounds (12/11/2008)Dr.Krock Dr.Vysetti Dr.Vysetti.

Optimizing the Management of Chronic Obstructive Pulmonary Disease (COPD) Note to the Speaker: All bold underlined statements must be read aloud to the.

What is Pneumonia and How Do I Prevent it?

COPD: Welcome to the 1 st Patient and Caregiver Support Series COPD: Support for Today, Solutions for Tomorrow To Join the Audio Conference: Dial (646)

Professor of Respiratory Medicine

Example Conference EBM format

Examining Emphysema and Chronic Bronchitis

22/06/2011.  Asthma – an introduction (Vanessa)  Diagnosis and management of chronic asthma in line with current BTS guidelines (Dr Lowery)  3 x Case.

Practice Support Program in COPD: South Okanagan Project COPD CARE Algorithm South Okanagan, Interior Health Patricia Rattee RRT, CRE Shannon Walker MD,

PROBLEM BASED LEARNING

Approach to bronchiectasis

D.B. Sanders, MD UW-Madison Parent Webinar PULMONARY EXACERBATION NUTS AND BOLTS.

Infections in acute exacerbation of COPD: are the agents the same ?

ROYAL WOLVERHAMPTON NHS TRUST ADULT COMMUNITY SERVICES LONG TERM CONDITIONS.

Budesonide/formoterol as effective as prednisolone plus formoterol in acute exacerbations of COPD A double-blind, randomised, non-inferiority, parallel-group,

Bronchiectasis Dilated airways with frequently thickened walls.

Pneumonia Dr. Meg-angela Christi Amores. Definition infection of the pulmonary parenchyma often misdiagnosed, mistreated, and underestimated community-acquired.

Antibiotic selection in the treatment of acute exacerbations of COPD Kurt A. Wargo, Pharm.D., BCPS(AQ-ID), Ryan E. Owens, Pharm.D. Candidate 2014, Takova.

Steroid Use in Acute Exacerbations of COPD Katherine Kielts, Pharm.D. PGY2 Critical Care Resident St. Vincent Indianapolis Hospital September 17, 2015.

Lung Cancer Case Presentation Presenter Date:. Educational Objectives.

Pulmonary-Allergy Drugs Advisory Committee May 1, 2007 FDA Presentation Advair Diskus 500/50 Carol Bosken, MD, ScM, MPH Medical Officer Division of Pulmonary.

Respiratory Physiology Diagnostics North East Glasgow Roger Carter Consultant Clinical Scientist.

1 COPD Phenotypes Stephen I Rennard University of Nebraska Florianopolis, Brazil October 2009.

Respiratory Emergencies. Respiratory Failure A condition that occurs when respiratory A condition that occurs when respiratory system is unable to adequately.

Respiratory Care A Life and Breath Career for You!

Variation in Outpatient Antibiotic use for Acute Respiratory Infections in the Veteran Population. Final Figures 1, 2, 3, 4, 5, 6.

Chapter 1 Introduction to Disease. Elsevier items and derived items © 2009 by Saunders, an imprint of Elsevier Inc. 1 Pathology at First Glance Homeostasis:

Exacerbations. Exacerbations An exacerbation of COPD is an acute event characterized by a worsening of the patient’s respiratory symptoms that is beyond.

New Concepts in Microbiology of Exacerbations of COPD Sanjay Sethi MD Professor Pulmonary, Critical Care and Sleep Medicine University at Buffalo, SUNY.

Management Of Exacerbations Of Chronic Obstructive Pulmonary Disease D.Anan Esmail Seminar Training Primary Care Asthma + COPD

Daniel B. Jamieson, Elizabeth C. Matsui, Andrew Belli1, Meredith C. McCormack, Eric Peng Simon Pierre-Louis, Jean Curtin-Brosnan, Patrick N. Breysse, Gregory.

Date of download: 6/3/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Inflammatory Biomarkers and Exacerbations in Chronic.

Management Of Exacerbations Of Chronic Obstructive Pulmonary Disease D.Anan Esmail Seminar Training Primary Care Asthma + COPD

COPD Emergency Department Junior Medical Staff Teaching August 2015.

COPD SPUTUM PRODUCERS AND THE INFLUENCE ON ANTIBIOTIC RESISTANCE Sarah Thurston PhD student.

Azithromycin – for better or worse in chronic lung infection? Professor Emma Baker Professor of Clinical Pharmacology St George's, University of London.

Oral Immunotherapy With Inactivated Nontypeable Haemophilus influenzae Reduces Severity of Acute Exacerbations in Severe COPD Maharaj Kishore Tandon, MD.

Acute Exacerbations of COPD

Assessment and Monitoring Asthma and Clinical Action Plan

COPD Tutoring – Part 1 By Alaina Darby.

Problem Case 호흡기 내과 R2 오원택.

^ Chest Diseases Ministry of health, Egypt

Poster Presentation Title

Bronchial Asthma Dr.Radhakrishna. S. A. Bronchial Asthma Dr.Radhakrishna. S. A.

COPD By Alaina Darby.

Overview The Burden of COPD Main Challenges in the Diagnosis of COPD.

Volume 143, Issue 1, Pages (January 2013)

Pneumonia Dr. Gerrard Uy.

Pseudomonas Infection in Cystic Fibrosis

Kaplan-Meier survival curves by frequency of exacerbations in patients with COPD: group A, patients with no acute exacerbations of COPD; group B, patients.

This talk will follow the topical structure suggested by the ABP:

Case Challenges in Chronic Migraine

CAP Therapy Babak Sayad Associate Professor of Infectious Diseases

Community Health Pearl:

Combination Inhaled Therapy in COPD: The Impact of Recent Data

Therapeutic Strategies in COPD Focus on Patient Characteristics and Drug Delivery.

Patrick A. Flume, John P. Clancy, George Z. Retsch-Bogart, D

D. Worlitzsch, C. Rintelen, K. Böhm, B. Wollschläger, N. Merkel, M

COPD Exacerbation (1) C.L.I.P.S.

Name of Hospital Presenter: Consultant Physician: Presentation Date:

Diagnosi della BPCO 1.

Clinical Challenges and Updates in Managing Seizure Clusters

Molecular analysis of changes in Pseudomonas aeruginosa load during treatment of a pulmonary exacerbation in cystic fibrosis D.W. Reid, R. Latham, I.L.

Medication in Patient Summaries

Global Initiative for Chronic Obstructive Lung Disease (GOLD) classification based on symptom and risk evaluation. a) GOLD model of symptom/risk evaluation.

D94- COPD: EPIDEMIOLOGY AND THERAPY

Kaplan-Meier survival curves by frequency of exacerbations in patients with COPD: group A, patients with no acute exacerbations of COPD; group B, patients.

Kaplan-Meier survival curves by severity of exacerbations in patients with COPD: (1) no acute exacerbations of COPD; (2) patients with acute exacerbations.

Presentation transcript:

(22%) (15%) (10%) (9%) (40%) (< 10% )

Pathology (sputum and bronchial biopsies)

Pathophysiology

Diagnostic and Therapeutic Approaches

Management of Acute of Exacerbation COPD

Summary

Factors Associated With Increased Risk for Exacerbations

Outpatient

Antibiotic treatment of acute exacerbations of COPD (Outpatient)

Pseudomonas risk factors: - Frequent administration of antibiotics (4 or more courses over the past year) - Recent hospitalization (2 or more days' duration in the past 90 days) - Isolation of Pseudomonas during a previous hospitalization - Severe underlying COPD (FEV1 <50 percent predicted) (Grade 2B)

Antibiotic treatment of acute exacerbations of COPD (hospitalized)